15th Feb 2005 15:15
15 February 2005Shire Pharmaceuticals Group plc (the "Company")The Company announces that on 11 November 2004, Dr James Cavanaugh, theChairman and a non executive director of the Company , acquired 296,571ordinary shares of ‚£0.05 each in the Company through a distribution from apartnership fund.As a result of this transaction, Dr Cavanaugh has a total interest in 412,849ordinary shares of ‚£0.05 in the Company. The Company was notified of DrCavanaugh's interest in these shares on 11 November 2004 .T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld +44 1256 894 160 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI), and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com.ENDRelated Shares:
Shire